Jardiance is an anti-diabetic drug owned by Boehringer Ingelheim and contains the active ingredient empagliflozin. It was first authorized for medical use in 2014. The anti-diabetes drugs market is projected to reach US$ 69 billion in 2023. There are 15 drug patents protecting Jardiance in United States, but as of now none of those patents have expired.
Jardiance (empagliflozin) currently has patent protection until December 11, 2034. Also, it has several exclusivities covering new indications and patient populations that expire between 2024 and 2026. This means Jardiance generics cannot launch until August 2026 when exclusivities end, unless there is a patent challenge.
Jardiance is approved for treating type 2 diabetes in adults. The active ingredient in Jardiance, empagliflozin, works by inhibiting the reabsorption of glucose in the kidneys and promoting excretion of excess glucose in the urine.
Jardiance currently has 14 patents covering the active ingredient, formulations, uses, and delivery methods. The earliest Jardiance patent expiration is in 2027, while the latest extend Jardiance generic launch until 2034, if no patent challenge filed. All Jardiance patent expirations are-